ArticleJournal of medicinal chemistry2020

Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.

Advait Nagle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.